Silexion Therapeutics Clinical Trial Data
Silexion Therapeutics has successfully dosed the first patient in its Phase 2/3 clinical trial of SIL204 for the treatment of locally advanced pancreatic cancer (LAPC). The trial evaluates SIL204 in combination with standard chemotherapy using a dual-route delivery strategy involving both intratumoral and subcutaneous administration. This milestone marks the transition of the company's lead RNAi program into active clinical execution across sites in Israel and Germany.
- Counterparty
- Tel Aviv Sourasky Medical Center